Observational studyMedicine2025
Changes of diamine oxidase and D-lactate in human breast and gynecologic cancers after chemotherapy.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the changes in diamine oxidase (DAO) and D-lactate levels in cancer patients undergoing chemotherapy and their clinical significance in evaluating intestinal barrier function. Breast and gynecologic cancer patients who received chemotherapy between January 2020 and December 2023 were enrolled from our hospital. Blood samples were taken before chemotherapy, within 3 days after chemotherapy, and before the next course of chemotherapy. The level of plasma DAO and D-lactate were measured by enzyme-linked immunosorbent assay (ELISA). After chemotherapy, nutritional markers such as albumin (ALB) and prealbumin (PAB) were evaluated. Anorexia, vomiting, nausea and diarrhea were evaluated during the chemotherapy cycle. There were no notable differences in serum DAO and D-lactate levels before chemotherapy among different tumor types, tumor stage and chemotherapy type. Serum DAO and D-lactate levels after chemotherapy were significantly elevated compared to their levels before chemotherapy (P < .05). The plasma DAO and D-lactate levels in cancer patients before the next course of chemotherapy were higher than those observed before the initial treatment, but the difference failed to achieve statistical significance (P > .05). The levels of DAO before chemotherapy were higher in patients with diarrhea and anorexia after chemotherapy than those without diarrhea and anorexia (P < .05). The levels of D-lactate before chemotherapy were notably elevated in patients with vomiting, diarrhea and nausea after chemotherapy than those without vomiting, diarrhea and nausea (P < .05). Monitoring serum levels of DAO and D-lactate in cancer patients undergoing chemotherapy can serve as indicators for evaluating gastrointestinal dysfunction and nutritional status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.